{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/fr\/","title":"Un iTK ciblant la mutation T790M dans les cas de cancer du poumon permet d\u2019obtenir des taux \u00e9lev\u00e9s de ma\u00eetrise de la maladie - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Rb8xXz4Mgq\"><a href=\"https:\/\/themedicalxchange.com\/fr\/2015\/10\/07\/congres-europeen-sur-le-cancer-de-2015-cec\/\">Un iTK ciblant la mutation T790M dans les cas de cancer du poumon permet d\u2019obtenir des taux \u00e9lev\u00e9s de ma\u00eetrise de la maladie<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/fr\/2015\/10\/07\/congres-europeen-sur-le-cancer-de-2015-cec\/embed\/#?secret=Rb8xXz4Mgq\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Un iTK ciblant la mutation T790M dans les cas de cancer du poumon permet d\u2019obtenir des taux \u00e9lev\u00e9s de ma\u00eetrise de la maladie\u00a0\u00bb &#8212; The Medical Xchange\" data-secret=\"Rb8xXz4Mgq\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2015\/10\/EX_7012_ECC_Fig_1_fr.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Vienne \u2013 Selon des donn\u00e9es pr\u00e9sent\u00e9es lors du Congr\u00e8s europ\u00e9en sur le cancer de 2015, un nouvel agent cibl\u00e9 utilis\u00e9 en deuxi\u00e8me intention ne cesse de produire des taux \u00e9lev\u00e9s de ma\u00eetrise de la maladie chez les patients atteints d\u2019une forme avanc\u00e9e de cancer du poumon non \u00e0 petites cellules (CPNPC) qui deviennent porteurs de la mutation T790M du r\u00e9cepteur du facteur de croissance \u00e9pidermique (R-EGF). Bien que les donn\u00e9es soient issues d\u2019essais de Phase II, l\u2019activit\u00e9 intense et le bilan d\u2019innocuit\u00e9 favorable de cet agent pourraient bien propulser ce dernier vers l\u2019homologation par les organismes de r\u00e9glementation."}